Share Twitter LinkedIn Facebook Email Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3 mutated relapsed/refractory acute myeloid leukemia (AML) that respond to gilteritinib.
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read